RESEARCH ARTICLE

Metabolic Disturbances in Adult-Onset Still’s Disease Evaluated Using Liquid Chromatography/Mass Spectrometry-Based Metabolomic Analysis

Der-Yuan Chen1,2,3, Yi-Ming Chen1,2,3☯, Han-Ju Chien5☯, Chi-Chen Lin3☯, Chia-Wei Hsieh2,3, Hsin-Hua Chen1,2,3, Wei-Ting Hung1,2, Chien-Chen Lai3,5*

1 Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan, 2 Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, 3 Ph.D. Program in Translational Medicine and Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan, 4 Institute of Biochemistry, Microbiology and Immunology, Chung-Shan Medical University, Taichung, Taiwan, 5 Institute of Molecular Biology, National Chung-Hsing University, Taichung, Taiwan

☯ These authors contributed equally to this work.
* lailai@dragon.nchu.edu.tw

Abstract

Objective

Liquid chromatography/mass spectrometry (LC/MS)-based comprehensive analysis of metabolic profiles with metabolomics approach has potential diagnostic and predictive implications. However, no metabolomics data have been reported in adult-onset Still’s disease (AOSD). This study investigated the metabolomic profiles in AOSD patients and examined their association with clinical characteristics and disease outcome.

Methods

Serum metabolite profiles were determined on 32 AOSD patients and 30 healthy controls (HC) using ultra-performance liquid chromatography (UPLC)/MS analysis, and the differentially expressed metabolites were quantified using multiple reactions monitoring (MRM)/MS analysis in 44 patients and 42 HC. Pure standards were utilized to confirm the presence of the differentially expressed metabolites.

Results

Eighteen differentially expressed metabolites were identified in AOSD patients using LC/MS-based analysis, of which 13 metabolites were validated by MRM/MS analysis. Among them, serum levels of lysoPC(18:2), urocanic acid and indole were significantly lower, and L-phenylalanine levels were significantly higher in AOSD patients compared with HC. Moreover, serum levels of lysoPC(18:2), PhePhe, uridine, taurine, L-threonine, and (R)-3-Hydroxy-hexadecanoic acid were significantly correlated with disease activity scores (all p<0.05) in AOSD patients. A different clustering of metabolites was associated with a different disease outcome, with significantly lower levels of isovaleryllysarcosine observed in...
patients with chronic articular pattern (median, 77.0 AU/ml) compared with monocyclic (341.5 AU/ml, p<0.01) or polycyclic systemic pattern (168.0 AU/ml, p<0.05).

**Conclusion**

Thirteen differentially expressed metabolites identified and validated in AOSD patients were shown to be involved in five metabolic pathways. Significant associations of metabolic profiles with disease activity and outcome of AOSD suggest their involvement in AOSD pathogenesis.

**Introduction**

Adult onset Still's disease (AOSD), a systemic inflammatory disease, is characterized by fever, skin rash, arthritis, hepatosplenomegaly, variable multisystemic involvement, liver dysfunction, hyperferritinemia, and increase in acute phase reactants [1–2]. Although AOSD pathogenesis is not completely understood, it is thought to involve dysregulated immune response, cytokine-mediated inflammation, interaction between host and environmental factors, and genetic complexity [3–10].

Metabolomics is a novel and quantitative method of analyzing metabolite changes in a cell, tissue, or body fluids [11–14]. Metabolomics can be used to investigate overall metabolic profiles, taking into account genetic and environmental factors, and allowing for the integration of the effects of these factors [15]. Among the analytical methods used in metabolomics research, liquid chromatography/mass spectrometry (LC/MS) has been shown to be one of the best techniques in terms of selectivity, sensitivity, and reproducibility [16–17]. Multivariate statistical analysis, unsupervised principal component analysis (PCA) and supervised partial least squares-discriminant analysis (PLS-DA) are the most widely utilized methods for stratifying the different metabolic profiles between a patient group and a control group [18]. Given the integrated nature of systemic metabolism, the analysis of multiple metabolites may provide a better understanding of disease-associated metabolic changes, and further elucidate the involvement of biological pathways.

Accumulating evidence suggests that the metabolite profile is altered in patients with rheumatic diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), and may be associated with disease activity [13,15,19–23]. The identification of metabolomic profiles in rheumatic diseases has provided insights into disease mechanisms, and highlighted their potential as biomarkers for diagnosis or prognosis [21–23]. Thus, we hypothesized that metabolomics could be used to detect disease-associated metabolic profiles, and identify metabolic biomarkers which may facilitate the diagnosis or prediction of disease outcome in AOSD. However, there are no data on the use of metabolomics in AOSD patients.

Therefore, this prospective study aimed to 1) identify the differentially expressed metabolites in AOSD patients using liquid chromatography/mass spectrometry (LC/MS)-based analysis, 2) quantify the differentially expressed metabolites using multiple reactions monitoring (MRM)/MS analysis, and 3) examine the associations of the altered metabolites with clinical characteristics and disease outcome in AOSD patients.

**Patients and Methods**

**Patients**

In this prospective study, 32 AOSD patients fulfilling the Yamaguchi criteria [24] were enrolled consecutively in the first stage of metabolomics analysis. In the replication analysis,
we enrolled other 12 AOSD cases from another independent cohort for validation of the differentially expressed metabolites derived from the first stage of metabolomics. Disease activity of AOSD was assessed with a modified Pouchot score described by Rau et al. [25]. Based on the proposed classification of disease courses of AOSD [26–27], we had follow-up of the AOSD patients for at least one year, and classified them into three kinds of courses: monocyclic systemic course (only one episode of systemic manifestations, followed by complete remission within one year after disease onset); polycyclic systemic course (more than one episode of systemic manifestations, followed by partial or complete remission after onset of the initial or the subsequent attack); and chronic articular course (persistent arthritis involving above one joint and lasting longer than 6 months). We recruited 40 healthy volunteers (30 for the first stage of analysis and 12 for the replication analysis) without history of rheumatic disease as a control group. The ethics committee of the Institutional Review Board of Taichung Veterans General Hospital had approved this study (CE13320), and the written consent was obtained according to the Declaration of Helsinki.

Serum samples preparation

Obtained from venous blood samples which were taken in the morning after an overnight fast for 12 hours, the serum samples were stored at -80°C until used for simultaneous determination of metabolic profiles. Prior to LC/MS analysis, 200μL of serum sample was mixed with 800μL of acetonitrile (Merck, NJ, USA), 5μL (50ppm) of esculetin and tubercidin, followed by vigorous vortex mixing for 2 min, and extraction with the aid of ultrasonication for 1 min. The sample mixtures were allowed to stand for 20 min at -20°C and then were centrifuged at 12,000 rpm for 30 min at 4°C. The supernatants of mixtures were transferred to new eppendorfs, and dried out with a turbovap nitrogen evaporator (AnytimeLabTrader, LLC, Oceanside, California, USA). Next, 100μL of mixture of acetonitrile–water (5:95 in volume) was added to each dried serum extract, and subsequently centrifuged at 12,000 rpm for 15 min at 4°C. The supernatants were then subjected to LC/MS analysis [16–17]. A quality control (QC) sample was prepared by mixing serum samples from 5 AOSD patients and 5 healthy subjects, and handled following the aforementioned procedure. The QC samples (1μL) were used for monitoring the stability of LC/MS analysis, and were continuously analyzed 3 times after 10 serum samples to validate the reproducibility of this platform (Fig 1A1–1A2).

Determination of metabolite profiles using LC/MS analysis

LC/quadrupole time-of-flight (QTOF)-MS (Maxis Impact, Bruker, MA, USA) equipped with an electrospray ionization (ESI) source was used for analysis of metabolite profile. LC/MS was operated in positive and negative ion mode by applying a voltage of 3,300 V for positive ESI (ESI⁺) and 2,500 V for negative ESI (ESI⁻). The temperature of the heated capillary in the ESI source was set at 200°C. Next, a collision energy (represented as a percentage of a maximum possible energy) sufficient to fragment the precursor ion was used to produce product ion spectra. In this metabolite analysis, data-dependent scanning was adopted; MS scan events were set as full mass scan, followed by MS/MS scans of the 3 highest-intensity precursor ions for collision-induced dissociation using 35eV. Other source parameters were set as follows: scan range for mass/charge ratio, 50–1000 m/z; drying gas flow, 7L/min; and pressure of nebulizer gas, 0.8 bars.

Chromatography using a Surveyor LC system

Eight microliter of the prepared sample was injected into a Waters Atlantis T3 C18 column (3 μm, 2.1 mm x 150 mm), and the eluent of the ultra-performance liquid chromatography
was directed to the ESI source of the mass spectrometer. The mobile phases consisted of a combination of solution A (0.1% formic acid in water) and solution B (0.1% formic acid in 100% acetonitrile). While maintaining a constant flow rate of 0.3 mL/min, the metabolites were eluted using linear gradients of 5–95% of B buffer from 0 to 14 min, and held at 95% of B buffer up to 17 min, after which it was decreased linearly to 5% at 17.1 min and held at 5% for 20 min until injection of the next analytical sample.

Data processing and pattern recognition

The experimental data of UPLC−QTOF-MS were processed by Profile Analysis (Bruker software). The intensity of fragment ion was normalized with respect to the total ion count to generate a data matrix consisting of the retention time, the m/z value, and the normalized peak area. The processed data were exported and further analyzed by unsupervised PCA using EZinfo 2.0 software (UpdateStar, Berlin, Germany) after unit variance (UV) scaling. To enhance the separation seen with the PCA, supervised partial least squares -discriminant analysis (PLS-DA) using the EZinfo Software 2.0 (UpdateStar, Berlin, Germany) and orthogonal projections to latent structures-discriminant analysis (OPLS-DA) using SIMCA 14, version 1 (Umetrics, NFI Co., Ltd.) was carried out. By focusing on the metabolites that contributed to the separation of AOSD patients and control group, multivariate models based on ParetoVariance (Par) scaling were established. Student’s t test with the critical p-value < 0.05 was selected to validate the significance of the metabolites selected. The corresponding fold change shows how these selected differential metabolites varied between the AOSD patients and control group. A probability of less than 0.05 was considered significant. The diagnostic sensitivity, specificity, and the area under receiver-operating characteristic (ROC) curve (AUC) were determined using SIMCA 14, version 1 (Umetrics, NFI Co., Ltd.).

Identification of the specific metabolites

The differential m/z values were selected using the criteria with both variable importance for projection (VIP) value more than 1.0 and p-value <0.05 in t-test. The identities of specific metabolites were confirmed by comparing the differential m/z values to commercially available reference standards. The specific metabolites were also identified at the Scripps Center for Metabolomics and Mass Spectrometry (METLIN) (http://metlin.scripps.edu/). The biochemical reactions associated with these identified metabolites were obtained from the Human Metabolome Database (HMDB) (http://www.hmdb.ca/), the Kyoto Encyclopedia of Genes and Genomes (KEGG) (http://www.genome.jp/kegg/), Massbank (http://www.massbank.jp/), and Chemspider (http://www.chemspider.com/).

Validation and quantification of the differentially expressed metabolites using MRM/MS analysis

UPLC analysis was performed on a Waters ACQUITY ultra performance LC system (Waters Corp., Milford, MA, USA), equipped with a binary solvent delivery system, an auto-sampler.
The chromatography was performed on a Waters Acquity UPLC Atlantis T3 Column (100Å, 3 μm, 2.1 mm X 100 mm). Binary mobile phases with phase A of water containing 0.1% formic acid (v/v) and phase B of ACN containing 0.1% formic acid (v/v) were used. The UPLC eluting conditions were optimized as follows: 0 min, 5% B; 14 min, 95% B; 17 min, 95% B; 17.1 min, 5% B; 20 min, 5% B. The total elapsed time required for a given chromatographic analysis was 20 min. The flow rate was 0.3 mL min⁻¹. The column and the auto-sampler were maintained at 35°C and 16°C, respectively, and the injection volume of sample was 8 μL.

Mass spectrometry was operated on a Waters Xevo TQ tandem quadrupole mass spectrometer (Micromass MS Technologies, Manchester, UK) using an ESI operated in both positive and negative ion mode. The desolvation gas was set to 800 L h⁻¹ at temperature of 400°C, and the source temperature was set to 150°C. The capillary voltage was set to 3.5 V, respectively. The collision gas flow was set at 0.21 mL min⁻¹. Detection was carried out in multiple reactions monitoring (MRM) mode. Fifteen MS/MS functions were performed in a single UPLC run, the details of parameters are shown in Table 1. Tubercidin and esculetin were used as internal standard of positive mode and negative mode, respectively.

Mapping of AOSD-specific metabolic profiling and biological pathway

AOSD-specific metabolic profiling was mapped by comparing the identified metabolites to available reference standards and their biological pathways were analyzed using the MetaboAnalyst (http://www.metaboanalyst.ca/) tool.

Table 1. Retention time and LC/MRM-MS parameters for 13 standard compounds and 2 internal standard.

| Compound Name     | Retention time tR (min) | Ion mode | Parent ion (m/z) | Daughter ion (m/z) | Dwell time (s) | Collision energy (V) | Cone voltage (V) |
|-------------------|-------------------------|----------|-----------------|-------------------|----------------|----------------------|-----------------|
| LysoPC(18:2)      | 11.81                   | Positive | 520.54          | 104               | 0.02           | 28                   | 38              |
| LysoPC(18:2)      | 11.81                   | Positive | 520.54          | 184.03            | 0.02           | 28                   | 38              |
| Indole            | 7.69                    | Positive | 117.99          | 90.88             | 0.328          | 20                   | 38              |
| L-threonine       | 0.96                    | Positive | 119.9           | 55.9              | 0.031          | 14                   | 16              |
| L-threonine       | 0.96                    | Positive | 119.9           | 83.86             | 0.031          | 12                   | 14              |
| Taurine           | 5.35                    | Positive | 125.8           | 98.3              | 0.019          | 8                    | 26              |
| Pyroglutamic acid | 1.45                    | Positive | 129.9           | 55.8              | 0.031          | 22                   | 22              |
| Pyroglutamic acid | 1.45                    | Positive | 129.9           | 83.85             | 0.031          | 32                   | 22              |
| Urocanolic acid   | 5.35                    | Positive | 138.95          | 65                | 0.019          | 26                   | 16              |
| Urocanolic acid   | 5.35                    | Positive | 138.95          | 92.84             | 0.019          | 64                   | 16              |
| L-phenylalanine   | 2.82                    | Positive | 165.9           | 102.91            | 0.151          | 26                   | 18              |
| L-phenylalanine   | 2.82                    | Positive | 165.9           | 130.91            | 0.151          | 14                   | 18              |
| Isovaleryllysacosine | 4.86                 | Positive | 174.05          | 89.9              | 0.1            | 8                    | 16              |
| Isovaleryllysacosine | 4.86                 | Positive | 174.05          | 84.89             | 0.1            | 12                   | 16              |
| Uridine           | 1.45                    | Positive | 245             | 112.8             | 0.031          | 12                   | 12              |
| Glutaryl carnitine | 1.77                  | Positive | 276.2           | 198.94            | 0.031          | 16                   | 28              |
| Glutaryl carnitine | 1.77                  | Positive | 276.2           | 84.81             | 0.031          | 24                   | 28              |
| PhePhe            | 5.34                    | Positive | 313.12          | 119.9             | 0.019          | 22                   | 20              |
| PhePhe            | 5.34                    | Positive | 313.12          | 165.95            | 0.019          | 16                   | 20              |
| p-Cresol sulfate  | 5.84                    | Negative | 186.98          | 106.89            | 0.086          | 22                   | 28              |
| p-Cresol sulfate  | 5.84                    | Negative | 186.98          | 79.81             | 0.086          | 28                   | 28              |
| Hydropalmitic acid | 14.49                 | Negative | 271.2           | 58.8              | 0.5            | 22                   | 28              |
| Tubercidin        | 1.39                    | Positive | 267.15          | 117.93            | 0.031          | 46                   | 24              |
| Tubercidin        | 1.39                    | Positive | 267.15          | 134.9             | 0.031          | 20                   | 24              |
| Esculetin          | 4.75                    | Negative | 177.04          | 104.87            | 0.005          | 20                   | 36              |
| Esculetin          | 4.75                    | Negative | 177.04          | 148.83            | 0.005          | 28                   | 34              |

doi:10.1371/journal.pone.0168147.t001
Statistical analysis

The results are presented as the mean ± standard deviation (SD) or median (interquartile range). The independent samples t test was used for between-group comparison of metabolites. Kruskal-Wallis test was used for between-group comparison of serum metabolites levels. When this test showed significant differences, the exact p-value was then determined using the Mann-Whitney U test. The correlation coefficient was obtained through the nonparametric Spearman’s rank correlation test. P values <0.05 were considered statistically significant.

Results

Clinical characteristics of AOSD patients

Among the 44 AOSD patients, 26 (59.1%) patients were in active status, which was defined as clinical activity score ≥3. Among active patients, fever (≥39 °C), rash, sore throat, arthritis, and lymphadenopathy were noted in 25 (96.2%), 19 (73.1%), 19 (73.1%), 14 (53.8%), and 12 (46.2%) patients respectively. There were no significant differences in the age at study entry (mean age ± standard deviation, 39.7 ± 15.3 years versus 35.0 ± 9.46 years), the proportion of females (33/44, 75.0% versus 33/42, 78.6%), serum creatinine levels, body mass index (BMI), or the proportion of past or present smoker between AOSD patients and healthy subjects.

Serum metabolite profiles in AOSD patients and healthy controls

Based on UPLC-QTOF-MS detection and PCA analysis, marked differences in total ion chromatogram (TIC), in ESI+ mode and ESI− mode, were observed between the patient group and the control group, with 907 positive ions and 1302 negative ions found. As illustrated in the OPLS-DA scores-plot, we observed different clustering of metabolites in the patient group and the control group in both ESI+ and ESI− modes (Fig 1A1–1A2). After the screening of VIP (value above 1), 18 differentially expressed metabolites were detected in AOSD patents, as summarized in Table 2. Then, we validated 13 of these 18 differentially expressed metabolites using LC/MRM-MS analysis with pure standards, the transitions and MS parameters were shown in Table 1. Among these 13 metabolites, median levels of serum lysoPC(18:2), urocanic acid and indole were significantly lower, and levels of L-phenylalanine were significantly higher in AOSD patients compared with HC (Fig 1). There was no significant difference in serum levels of other metabolites between AOSD patients and the control group.

Regarding the performance in disease diagnosis, the ROC curve analysis (the patient group versus the control group) revealed that the AUC reached 0.95 (p<0.01) with a high specificity (96.7%) and moderate sensitivity (78.1%) in the first stage of metabolomics, and the AUC reached 0.972 (p<0.001) with a high specificity (100%) and high sensitivity (91.67%) in the replication analysis.

Association of metabolites with disease activity or clinical manifestations

As illustrated in the OPLS-DA scores-plot, different clustering of metabolic ions was noted among active AOSD patients, inactive AOSD patients, and the control group (Fig 2A1 and S1 Fig). Different clustering of metabolites was also observed in AOSD patients with different activity scores (Fig 2A2 and S2 Fig). Among the differentially expressed metabolite, serum levels of lysoPC(18:2), PhePhe, taurine, and L-threonine were negatively correlated, while levels of (R)-3Hydroxy-hexadecanoic acid were positively correlated with clinical activity scores in AOSD patients (Fig 2B–2N). However, there were no significant associations of the differentially expressed metabolite with clinical manifestations in AOSD patients.
The association of metabolomic profiles with disease outcome in AOSD patients

As illustrated in the OPLS-DA scores-plot, AOSD patients with different patterns of disease outcome revealed different clustering of metabolites (Fig 3A). Moreover, significantly lower levels of isovalerylsarcosine were observed in AOSD patients with chronic articular pattern (median, 77.0AU/ml) compared with those with monocyclic systemic (341.5AU/ml, p < 0.05) or polycyclic systemic pattern (168.0AU/ml, p < 0.05) (Fig 3). There was no significant association of disease outcome with other metabolites.

AOSD-specific metabolic mapping and biological pathway

As illustrated in Fig 4, the most discriminative metabolites in AOSD were organized into different biochemical pathways, including amino acid metabolism, fatty acid biosynthesis, phospholipid metabolism, taurine metabolism, and pentose phosphate metabolism.

Discussion

LC/MS-based metabolomics approach has potential implications for disease diagnosis and prediction [18,28–30]. Our study is the first to use UPLC-QTOF/MS-based metabolomics to...
reveal 18 differentially expressed metabolites in AOSD patients compared with healthy subjects, and then use LC/MRM-MS analysis to validate 13 metabolites in replication cohort with a high AUC and specificity. These significant metabolites, as shown in Fig 4, are potentially involved in the metabolism of amino acid, fatty acid, phospholipid, taurine, and pentose phosphate. Moreover, serum levels of lysoPC(18:2), PhePhe, uridine, taurine, L-threonine, and (R)-3-Hydroxy-hexadecanoic acid were significantly correlated with clinical activity scores (all p<0.05) in AOSD patients. Significantly lower levels of isovalerylsarcosine were also observed in patients with chronic articular pattern compared with other patterns of disease outcome in AOSD. These observations suggest these altered metabolites might be involved in AOSD pathogenesis.

Using standard compounds and LC/MRM-MS analysis, we revealed significantly lower levels of lysoPC(18:2), urocanic acid and indole in AOSD patients compared with the control group. LysoPC(18:2) is one of the class of phospholipids that are intermediates in the metabolism of phospholipids [31]. The abnormal metabolism of phospholipid may promote the systemic inflammatory state [32]. In our study, the decreased levels of lysoPC(18:2) in AOSD patients may indicate its potential protective effect against inflammatory response and suggest its augmented consumption in apoptotic processes in this disease [33]. Urocanic acid is one metabolite which is involved histidine metabolism. The results of a recent study showed urocanic acid derivatives have anti-inflammatory effects on inflammatory bowel disease [34], supporting the decreased levels of urocanic acid in our AOSD patients. Indole, another important metabolite, is a product of amino acid (tryptophan) metabolism. We revealed the decreased indole levels in AOSD patients, which was similar to previous finding that tryptophan was down-regulated in patients with ankylosing spondylitis compared with controls [35], and suggested the depletion of tryptophan during inflammation may serve as a damping effect. Interestingly, p-Cresol sulfate (PCS), solely produced by the gut microbiota, can enhance the production of reactive oxygen species and then activate the nuclear factor-kappaB pathway, resulting in both oxidative stress and pro-inflammatory cytokine production [36]. Although the statistical significance was not reached (p = 0.095), decreased PCS levels in our patients might indicate the down-regulation of inflammatory and oxidative mechanisms in AOSD. These findings may link the altered microbial metabolites with the pathogenesis of rheumatic diseases [22]. In contrast, we revealed significantly higher levels of L-phenylalanine in patients compared with the control group. The results supported the findings of other previous studies showing that phenylalanine levels increased in chronic inflammation [37] and the urine phenylalanine levels increased in adjuvant-induced arthritis rats [38].

In this study, the different clustering of metabolites observed in AOSD patients with different activity scores indicated that the status of inflammation could be reflected in the metabolic profiles [15]. As shown in Fig 2, serum levels of lysoPC(18:2), PhePhe, uridine, taurine, L-threonine, and (R)-3-Hydroxy-hexadecanoic acid were significantly correlated with activity scores (all p<0.05) in AOSD patients. Interestingly, we also demonstrated differential clustering of metabolites between inactive AOSD patients and healthy subjects, as shown in Fig 2A1, suggesting that the disease remission state in AOSD is not the result of total normalization of metabolic change. Longitudinal studies will be needed to monitor the change in metabolites before and after treatment in order to identify biomarkers helpful for optimizing therapy as in previous studies [23].
The disease course of AOSD patients may vary considerably [26–27]. OPLS-DA plot, as shown in Fig 3A, demonstrated different clustering of metabolites among different patterns of disease outcome in AOSD patients. Among the differentially expressed metabolites, serum levels of isovalerylsarcosine were significantly lower in AOSD patients with chronic articular pattern compared with other patterns of disease outcome. Isovalerylsarcosine, an important metabolite, is a product of glycine, serine and threonine metabolism. A decrease in serine and threonine content of the cartilage proteoglycan in antigen-induced arthritis of rabbit [39], supporting our findings showing the decreased levels of isovalerylsarcosine in AOSD patients with chronic articular pattern of disease outcome.

As illustrated in Fig 4, the multiple potential biochemical pathways involved in AOSD-related metabolomic profiling highlight the complexity of the metabolic response to systemic inflammation in this disease. Because the serum samples represent a cross-section of metabolic

Fig 3. A different clustering of metabolic ions in the OPLS-DA score plots from AOSD patients with different patterns of disease outcome (A). The comparisons in serum levels of the differentially expressed metabolites in AOSD patients with different patterns of disease outcome (B-N). *p<0.05, versus monocylic systemic pattern or polycyclic systemic pattern. The explanations for box plots are as those described in Fig 1 legend.

doi:10.1371/journal.pone.0168147.g003

Fig 4. Schematic representation depicts the metabolic imbalance in patients with adult-onset Still’s disease (AOSD). (↑) represents up-regulated changes observed in AOSD; (↓) represents down-regulated changes observed in AOSD.

doi:10.1371/journal.pone.0168147.g004
events reacting to multiple independent triggers, it is probable that subsets of these metabolic changes are interconnected, and/or associated with immune activation in AOSD.

This pilot study still had some limitations. The lack of significant associations of the differentially expressed metabolites with clinical features may be due to the small sample size in this clinically heterogeneous and rare disease: its prevalence estimated to be lower than 1 case per 100,000 people [40]. This study was cross-sectional in design and thus it is possible that the metabolic profiles could alter with disease progression or therapeutic strategies. In addition, we did not elucidate the biological function of these metabolites. Future studies dissecting the functional roles and pathogenic mechanisms of these significant metabolites are clearly needed.

Conclusions

Our metabolomics based on both UPLC/TOF-MS and LC/MRM-MS analysis identified 13 differentially expressed metabolites which were associated with the metabolism of amino acid, fatty acid, phospholipid, taurine and pentose phosphate in AOSD. Significant associations of metabolic profiles with disease activity and outcome suggest their involvement in AOSD pathogenesis. The diagnostic or prognostic utility of these altered metabolites need to be evaluated by studies with a larger number of AOSD patients or of other phenotypically similar diseases [20,41].

Supporting Information

S1 Fig. The loading plot for the OPLS-DA score plot from 14 active AOSD patients, 18 inactive AOSD patients, and 30 healthy controls.
(TIF)

S2 Fig. The loading plot for the OPLS-DA modeling plot from AOSD patients with different disease activity scores.
(TIF)

Acknowledgments

This work was supported by a grant from Taichung Veterans General Hospital and National Chung Hsing University (TCVGH-NCHU1037601 and TCVGH-NCHU1057601). The authors thank the Biostatistics Task Force of Taichung Veterans General Hospital, Taichung, Taiwan.

Author Contributions

Conceptualization: DYC C. Lai.
Data curation: HJC.
Formal analysis: YMC HJC C. Lin CWH HHC WTH.
Funding acquisition: DYC C. Lia.
Investigation: DYC YMC HJC C. Lin CWH HHC WTH C. Lai.
Methodology: YMC HJC C. Lin C. Lai.
Project administration: DYC C. Lai.
Resources: DYC HJC C. Lin C. Lai.
Supervision: DYC C. Lai.
Validation: DYC HJC C. Lai.
Visualization: DYC YMC HJC C. Lai.
Writing – original draft: DYC.
Writing – review & editing: DYC YMC HJC C. Lin CWH HHC WTH C. Lai.

References

1. Gerfaud-Valentin M, Maucort-Boulch D, Hot A, Iwaz J, Ninet J, Durieu I, et al. Adult-onset Still's disease: manifestations, treatment, and prognostic factors in 57 patients. Medicine (Baltimore) 2014; 93:91–9.
2. Rosśário C, Zandman-Goddard G, Meyron-Holtz EG, D'Cruz DP, Shoenfeld Y. The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med 2013; 11:185. doi: 10.1186/1741-7015-11-185 PMID: 23968282
3. Fuji T, Nojima T, Yasuoka H, Satoh S, Nakamura K, Kuwana M, et al. Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease: association with chronic articular disease. Rheumatology 2001; 40:1398–1404. PMID: 11752512
4. Choi JH, Suh CH, Lee YM, Suh YJ, Lee SK, Kim SS, et al. Serum cytokine profiles in patients with adult onset Still's disease. J Rheumatol 2003; 30:2422–7. PMID: 14677188
5. Chen DY, Lan JL, Lin FJ, Hsieh TY, Wen MC. A predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult-onset Still's disease. Ann Rheum Dis 2004; 63:1300–6. doi: 10.1136/ard.2003.013680 PMID: 15361391
6. Chen DY, Chuang HC, Lan JL, Chen YM, Hung WT, Lai KL, et al. Germlinal Center Kinase (GCK)-Like Kinase (GLK/MAP4K3) Expression Is Increased in Adult-Onset Still's Disease and May Act as an Activity Marker. BMC medicine 2012; 10:84. doi: 10.1186/1741-7015-10-84 PMID: 22867055
7. Kadavath S, Efthimiou P, Adult-onset Still's disease-pathogenesis, clinical manifestations, and new treatment options. Ann Med 2015; 22:1–9.
8. Wouters JMGW, van der Veen J, van de Putte LBA, de Rooij DJRAM. Adult Still's disease and viral infection. Ann Rheum Dis 1988; 47:764–7. PMID: 3178317
9. Sugitani T, Kagawuchi Y, Harigai M, Terajima-Ichida H, Kitamura Y, Furuya T, et al. Association between adult-onset Still's disease and interleukin-18 gene polymorphisms. Genes Immun 2002; 3:394–9. doi: 10.1038/sj.gene.6363922 PMID: 12424620
10. Chen DY, Chen YM, Chen HH, Hsieh CW, Lin CC, Lan JL. Functional Association of IL-18 Gene –607 (C/A) Promoter Polymorphisms with Disease Course in Chinese Patients with Adult-Onset Still's Disease. J Rheumatol 2009; 36:2284–2289. doi: 10.3899/jrheum.090316 PMID: 19684151
11. Pearson H. Meet the human metabolome. Nature 2007; 446:8–8. doi: 10.1038/446008a PMID: 17330009
12. Blanchet L, Smolinska A, Attali A, Stoop MP, Ampt KA, van Aken H, et al. Fusion of metabolomics and proteomics data for biomarkers discovery: case study on the experimental autoimmune encephalomyelitis. BMC Bioinformatics 2011; 12:254. doi: 10.1186/1471-2105-12-254 PMID: 2169593
13. Romyck-Rosendale LE, Brunner HI, Bennett MR, Mina R, Nelson S, Petri M, et al. Identification of urinary metabolites that distinguish membranous lupus nephritis from proliferative lupus nephritis and focal segmental glomerulosclerosis. Arthritis Res Thera 2011; 13:R199.
14. Sun J, Shannon M, Ando Y, Schnackenberg LK, Khan NA, Portilla D, et al. Serum metabolic profiles from patients with acute kidney injury: a pilot study. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 893:107–13. doi: 10.1016/j.jchromb.2012.02.042 PMID: 22429878
15. Young SP, Kapoor SR, Viant MR, Byrne JJ, Filer A, Buckley CD, et al. The impact of inflammation on metabolomic profiles in patients with arthritis. Arthritis Rheum 2013; 65:2015–23. doi: 10.1002/art.38021 PMID: 23740368
16. Nordstrom A, O'Maille G, Qin C, Sluzdak G. Nonlinear data alignment for UPLC-MS and HPLC-MS based metabolomics: quantitative analysis of endogenous and exogenous metabolites in human serum. Analytical Chem 2006; 78:3289–3295.
17. Theodoridis G, Gika HG, Wilson ID. LC-MS-based methodology for global metabolite profiling in metabonomics/metabolomics. TRAC Trends Analytical Chem 2008; 27:251–260.
18. Priori R, Scrivo R, Brandt J, Valerio M, Casadei L, Valesini G, et al. Metabolomics in rheumatic diseases: the potential of an emerging methodology for improved patient diagnosis, prognosis, and treatment efficacy. Autoimmu Rev 2013; 12:1022–30.

19. Wu T, Xie C, Han J, Ye Y, Wei J, Li Q, et al. Metabolic Disturbances Associated with Systemic Lupus Erythematosus. PLoS ONE 2012; 7:e37210. doi: 10.1371/journal.pone.0037210 PMID: 22723834

20. Madsen RK, Lundstedt T, Gabrielson J, Sennbro CJ, Alenius GM, Moritz T, et al. (2011) Diagnostic properties of metabolic perturbations in rheumatoid arthritis. Arthritis Rheum 2011; 13:R19. doi: 10.1186/ar3243 PMID: 21030541

21. Poulopoulou C, Papadopoulou-Daifoti Z, Hatzimanolis A, Fragiadaki K, Polissidis A, Anderzanova E, et al. Glutamate levels and activity of the T-cell voltage-gated potassium Kv1.3 channel in patients with systemic lupus erythematosus. Arthritis Rheum 2008; 58:1445–1450. doi: 10.1002/art.23446 PMID: 18438846

22. Rojo D, Hevia A, Bargiela R, López P, Cuervo A, González S, et al. Ranking the impact of human health disorders on gut metabolism: systemic lupus erythematosus and obesity as study cases. Scientific Reports 2015; 5:8310.

23. Kapoor SR, Filer A, Fitzpatrick MA, Fisher BA, Taylor PC, Buckley CD, et al. Metabolic profiling predicts response to anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis. Arthritis Rheum 2013; 65:1448–56. doi: 10.1002/art.37921 PMID: 23460124

24. Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol 1999; 19:424–30. PMID: 10578458

25. Rau M, Schiller M, Krienke S, Heyder P, Lorenz H, Blank N. Clinical manifestations but not cytokine profiles differentiate adult-onset Still’s disease and sepsis. J Rheumatol 2010; 37:2369–76. doi: 10.3899/jrheum.100247 PMID: 20810496

26. Cush JJ, Medsger TA, Christy WC, Herbert DC, Cooperstein LA. Adult-onset Still’s disease: clinical course and outcome. Arthritis Rheum 1987; 30:186–94. PMID: 3827959

27. Mavragani CP, Spyridakis EG, Koutsilieris M. Adult-onset Still’s disease: from pathophysiology to targeted therapies. Int J Inflamm 2012; 2012:897020.

28. Scrivo R, Casadei L, Valerio M, Priori R, Valesini G, Manetti C. Metabolomics approach in allergic and rheumatic diseases. Curr Allergy Asthma Rep 2014; 14:445. doi: 10.1007/s11882-014-0445-5 PMID: 24744271

29. Semerano L, Roméo PH, Boissier MC. Metabolomics for rheumatic disease: has the time come. Ann Rheum Dis 2015; 74:1325–26. doi: 10.1136/annrheumdis-2014-206618 PMID: 25609411

30. García-Simón M, Morales JM, Modesto-Alapont V, Gonzalez-Marrachelli V, Vento-Rehues R, Jordá-Miñana A, et al. Prognosis biomarkers of severe sepsis and septic shock by 1H NMR urine metabolomics in the intensive care unit. PLOS ONE 2015; 10:e0140993. doi: 10.1371/journal.pone.0140993 PMID: 26565633

31. Vance JE. Phosphatidyleserine and phosphatidylethanolamine in mammalian cells: two metabolically related aminophospholipids. J Lipid Res 2008; 49:1377–87. doi: 10.1194/jlr.R700020-JLR200 PMID: 18204094

32. Manzi S, Wasko MC. Inflammation-mediated rheumatic diseases and atherosclerosis. Ann Rheum Dis 2000; 59:321–5. doi: 10.1136/ard.59.5.321 PMID: 10784507

33. Chen DY, Hsieh TY, Hsieh CW, Lin FJ, Lan JL. Increased apoptosis of peripheral blood lymphocytes and its association with interleukin-18 in patients with active untreated adult-onset Still’s disease. Arthritis & Rheumatism (Arthritis Care and Research) 2007; 57:1530–1538.

34. Kammeyer A, Peters CP, Meijer SL, Te Velde AA. Anti-inflammatory effects of urocanic acid derivatives in models ex vivo and in vivo of inflammatory bowel disease. ISRN Inflamm 2012; 2012:898153. doi: 10.5402/2012/898153 PMID: 24049652

35. Gao P, Lu C, Zhang F, Sang P, Yang D, Li X, et al. Integrated GC-MS and LC-MS plasma metabolomics analysis of ankylosing spondylitis. Analyst 2008; 133:1214–20. doi: 10.1039/b807369d PMID: 18707936

36. Watanabe H, Miyamoto Y, Honda D, Tanaka H, Wu Q, Endo M, et al. p-Cresol sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase. Kidney Int 2013; 83:582e592.

37. Neurauteur G, Schröcksnadel K, Scholl-Bürgi S, Sperner-Unterweger B, Schubert C, Ledochowski M, et al. Chronic immune stimulation correlates with reduced phenylalanine turnover. Curr Drug Metab 2008; 9:622–27. PMID: 18781914

38. Qi Y, Pi Z, Liu S, Song F, Lin N, Liu Z. A metabolomics study of adjuvant-induced arthritis in rats using ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. Mol BioSyst 2014; 10:2617–25. doi: 10.1039/c4mb00131a PMID: 25041942
39. Shimizu K. Studies on the biochemical alterations of cartilage proteoglycan in antigen-induced arthritis of rabbit. Nihon Seikeigeka Gakkai Zasshi. 1981; 55:755–67. PMID: 6796634

40. Evensen KJ, Nossent HC. Epidemiology and outcome of adult-onset Still’s disease in Northern Norway. Scand J Rheumatol 2006; 35:48–51. doi: 10.1080/03009740510026616 PMID: 16467042

41. Jiang M, Chen T, Feng H, Zhang Y, Li L, Zhao A, et al. Serum metabolic signatures of four types of human arthritis. J Proteome Res 2013; 12:3769–79. doi: 10.1021/pr400415a PMID: 23819623